ANNX

Rating neutralAI Memo

Annexon

As of 2026-09-03/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

ANX1502 proof-of-concept data • 2026-10-31

Base target: $7 / p=50% prob

Biggest risk

The thesis remains highly binary: ARCHER II could disappoint, the FDA could require additional generalizability data for tanruprubart, and delays could increase financing or dilution risk. Analyst revision evidence is unavailable, so the positive deterministic signal should not be treated as confirmation.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

ANNX has multiple dated 2026 catalysts across two advanced programs: ARCHER II Phase 3 data in GA and a planned tanruprubart BLA supported by FORWARD data. Positive early FORWARD outcomes and a strengthened runway could support a meaningful re-rating if execution continues [#SEC-8K-2026-08-12].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Improved balance-sheet runway
ANNX has multiple dated 2026 catalysts across two advanced programs: ARCHER II Phase 3 data in GA and a planned tanruprubart BLA supported by FORWARD data.
Positive early FORWARD outcomes and a strengthened runway could support a meaningful re-rating if execution continues [#SEC-8K-2026-08-12].

BearKey bullets

Binary Phase 3 efficacy and safety risk for ARCHER II.
Clinical-development delays or weaker-than-expected FORWARD or ANX1502 results.
Low analyst coverage and unavailable consensus, estimate-revision, and post-print market-reaction data.

WatchKey bullets

ANX1502 proof-of-concept data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $7 (p=50%)

Target spread vs base: +85% / -62%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $7 (p=50%)Bear Target: $3 (p=25%)

Commentary

The latest company update is constructive, with stronger runway and several dated clinical or regulatory milestones. However, coverage is low, social data are absent, analyst revisions and consensus are unavailable, and post-update price reaction is not established in the packet. Sentiment therefore supports cautious monitoring rather than a high-conviction directional call.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Improved balance-sheet runway

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$7 / p=50% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.50

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
ANX1502 proof-of-concept data
Proof-of-concept data for the oral C1 inhibitor ANX1502 are expected in fall 2026, offering an additional but earlier-stage pipeline readout [#SEC-8K-2026-08-12].
Prob 45.00% • Move 25.00% • Priced-in 20.00%
EVENT2026-11-15
ARCHER II Phase 3 topline data
Month-15 primary-endpoint data for vonaprument in geographic atrophy are expected in Q4 2026. This is the principal valuation catalyst, but the outcome remains binary for a late-stage asset [#SEC-8K-2026-08-12].
Prob 50.00% • Move 60.00% • Priced-in 30.00%
EVENT2026-12-31
Tanruprubart FORWARD data and BLA path
Annexon reports positive early outcomes in the FORWARD study, with a U.S. BLA submission expected in Q4 2026 and the European MAA under review. Regulatory generalizability and execution remain important uncertainties [#SEC-8K-2026-08-12] [#10-K-2026-03-30].
Prob 60.00% • Move 35.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Improved balance-sheet runway
2026-09-30
The company announced a $200 million credit facility and expects runway into 2028, reducing near-term financing pressure while dilution risk remains relevant [#SEC-8K-2026-08-12] [#10-K-2026-03-30].
Prob 80% • Move 8% • Priced-in 70%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Binary Phase 3 efficacy and safety risk for ARCHER II.
Clinical-development delays or weaker-than-expected FORWARD or ANX1502 results.
Low analyst coverage and unavailable consensus, estimate-revision, and post-print market-reaction data.
Potential dilution from future equity issuance or the disclosed ATM facility.
Regulatory risk, including possible requests for additional tanruprubart data.

Peers

Symbol	Summary
CLYM	Same-sector, approximately $1 billion market-cap comparator; useful for development-stage biotech volatility, but no direct indication or mechanism match is confirmed.
DSGN	Same-sector, approximately $1 billion market-cap comparator; relevant for readout and financing sensitivity, but a loose peer rather than a direct operating comparable.
JANX	Same-sector, approximately $1 billion market-cap comparator; useful as a small-cap biotech valuation check, with limited direct comparability established in the packet.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

CLYM

Same-sector, approximately $1 billion market-cap comparator; useful for development-stage biotech volatility, but no direct indication or mechanism match is confirmed.

DSGN

Same-sector, approximately $1 billion market-cap comparator; relevant for readout and financing sensitivity, but a loose peer rather than a direct operating comparable.

JANX

Same-sector, approximately $1 billion market-cap comparator; useful as a small-cap biotech valuation check, with limited direct comparability established in the packet.